Dulaglutide for Appetite Control
Research, mechanism, dosing, and effectiveness of Dulaglutide for appetite control.
Quick Answer
Provides steady appetite suppression with weekly dosing.
Evidence Level
FDA Approved
Typical Dose
1.5-4.5 mg weekly
Results Timeline
Appetite control within 1-2 weeks
FDA Status
FDA Approved
How Dulaglutide Works for Appetite Control
Sustained GLP-1 action reduces hunger between doses.
About Appetite Control
Suppression of hunger signals and improved satiety for weight management.
Research Evidence
AWARD program showed significant A1C reduction and weight loss. REWIND trial demonstrated cardiovascular benefits in broader diabetic population. Generally shows 3-5% weight loss in trials.
Dosing for Appetite Control
Recommended Dose
1.5-4.5 mg weekly
Frequency
Once weekly
Administration
Subcutaneous injection weekly
Duration
Long-term / chronic use
Note: FDA-approved as Trulicity. Titrate from 0.75 mg. Convenient once-weekly dosing.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Nausea
- •Diarrhea
- •Vomiting
- •Abdominal pain
- •Injection site reactions
- •Hypoglycemia (with insulin/sulfonylureas)
Frequently Asked Questions
Does Dulaglutide help with appetite control?
Provides steady appetite suppression with weekly dosing.
How does Dulaglutide work for appetite control?
Sustained GLP-1 action reduces hunger between doses....
What dose of Dulaglutide should I use for appetite control?
1.5-4.5 mg weekly
How long until I see results?
Appetite control within 1-2 weeks
Other Peptides for Appetite Control
These peptides are also researched for appetite control.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Tirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Liraglutide
FDAAn FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Exenatide
FDAThe first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.
Educational Information Only
This information about Dulaglutide for appetite control is for educational purposes only. Always consult with qualified healthcare providers before using any peptide. Individual results may vary.